Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Apple
AAPL
|
$391M |
| 2 |
Amazon
AMZN
|
$361M |
| 3 |
Microsoft
MSFT
|
$358M |
| 4 |
Meta Platforms (Facebook)
META
|
$196M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$171M |
Top Sells
| 1 |
Alibaba
BABA
|
$1.07B |
| 2 |
Newmont
NEM
|
$141M |
| 3 |
Eli Lilly
LLY
|
$125M |
| 4 |
Waste Management
WM
|
$124M |
| 5 |
McDonald's
MCD
|
$112M |
Sector Composition
| 1 | Technology | 27.15% |
| 2 | Healthcare | 14.17% |
| 3 | Consumer Discretionary | 13.28% |
| 4 | Communication Services | 11.57% |
| 5 | Industrials | 8.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Atea Pharmaceuticals
AVIR
$259M
| $784K | ﹤0.01% |
+36,500
| New | +$784K |
|
2552
Forestar Group
FOR
$1.45B
| $776K | ﹤0.01% |
37,117
-1,200
| -3% | -$25.1K |
|
2553
Applied Therapeutics
APLT
$66.9M
| $775K | ﹤0.01% |
37,300
+2,700
| +8% | +$56.1K |
|
2554
CEL-SCI Corp
CVM
$71.6M
| $775K | ﹤0.01% |
2,977
+210
| +8% | +$54.7K |
|
2555
Capital City Bank Group
CCBG
$739M
| $766K | ﹤0.01% |
29,700
+2,900
| +11% | +$74.8K |
|
2556
ANI Pharmaceuticals
ANIP
$2.06B
| $764K | ﹤0.01% |
21,800
-600
| -3% | -$21K |
|
2557
BioAtla
BCAB
$35.6M
| $763K | ﹤0.01% |
+18,000
| New | +$763K |
|
|
ATSG
2558
DELISTED
Air Transport Services Group, Inc.
ATSG
| $763K | ﹤0.01% |
32,850
-1,000
| -3% | -$23.2K |
|
2559
Annexon
ANNX
$238M
| $756K | ﹤0.01% |
33,600
+3,400
| +11% | +$76.5K |
|
2560
FRP Holdings
FRPH
$488M
| $752K | ﹤0.01% |
27,000
-1,000
| -4% | -$27.9K |
|
|
ISEE
2561
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $748K | ﹤0.01% |
118,500
-43,400
| -27% | -$274K |
|
2562
Geron
GERN
$880M
| $743K | ﹤0.01% |
526,600
-176,800
| -25% | -$249K |
|
2563
MeiraGTx Holdings
MGTX
$603M
| $741K | ﹤0.01% |
47,800
-1,600
| -3% | -$24.8K |
|
|
SCR
2564
DELISTED
Score Media and Gaming Inc. Class A Subordinate Voting Shares
SCR
| $737K | ﹤0.01% |
+36,700
| New | +$737K |
|
2565
Cullinan Oncology
CGEM
$407M
| $736K | ﹤0.01% |
+28,600
| New | +$736K |
|
2566
CytomX Therapeutics
CTMX
$361M
| $736K | ﹤0.01% |
116,200
| – | – |
|
2567
Kiniksa Pharmaceuticals
KNSA
$2.7B
| $736K | ﹤0.01% |
52,800
-1,400
| -3% | -$19.5K |
|
|
DSPG
2568
DELISTED
DSP Group Inc
DSPG
| $731K | ﹤0.01% |
49,400
-1,800
| -4% | -$26.6K |
|
2569
KRONOS Worldwide
KRO
$733M
| $729K | ﹤0.01% |
50,900
-1,900
| -4% | -$27.2K |
|
2570
Lifecore Biomedical
LFCR
$275M
| $727K | ﹤0.01% |
64,600
+4,700
| +8% | +$52.9K |
|
2571
ON24
ONTF
$236M
| $724K | ﹤0.01% |
+20,400
| New | +$724K |
|
|
FLXN
2572
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $724K | ﹤0.01% |
88,011
-12,300
| -12% | -$101K |
|
2573
Zynex
ZYXI
$44.2M
| $716K | ﹤0.01% |
50,710
+3,190
| +7% | +$45K |
|
2574
ARS Pharmaceuticals
SPRY
$1.05B
| $714K | ﹤0.01% |
+23,100
| New | +$714K |
|
2575
Vital Farms
VITL
$2.21B
| $713K | ﹤0.01% |
35,700
| – | – |
|